A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Patients in the pembrolizumab group also tended to have better quality of life based on a symptom score calculated from the seven items of the Lung Cancer Subscale of the Functional Assessment of ...

Lung cancer that is RET-positive may be able to ... or with platinum-based chemotherapy with or without a medicine called pembrolizumab. The group of people who did not receive Retevmo were ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

then pembrolizumab alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. Pembrolizumab, also known as Keytruda, is given as an infusion and is a monoclonal antibody which ...

N-803 has cleared phase Ib/II clinical trials 3, specifically in patients with metastatic, non-small cell lung cancer (NSCLC) who no longer respond to pembrolizumab alone. Based on preliminary ...

NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with advanced solid tumors and lung cancer, ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

The trial will enrol patients with mCRC who are microsatellite stable (MSS), wild type (WT) RAS, WT BRAF, and human epidermal ...

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research ...

Following treatment with NUC-3373 plus pembrolizumab, this patient achieved a confirmed Partial Response with an 81% reduction in the target lesion and remains on treatment for over 12 months. Module ...